quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

D-Wave Quantum (QBTS) Q3 2024 Earnings Transcript

View original at finance.yahoo.com
D-Wave Quantum (QBTS) Q3 2024 Earnings Transcript Image source: The Motley Fool. Date Thursday, November 14, 2024 at 8 a.m. ET Call participants Chief Executive Officer — Alan Baratz Chief Financial Officer — John Markovich Need a quote from a Motley Fool analyst?…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 revenue expected to improve over Q3

    80% confidence
  • NTT DOCOMO deployment achieved 15% reduction in network congestion, solving in 40 seconds vs 27 hours classical compute

    80% confidence
  • Leap Quantum Cloud Service has achieved 99.9%+ availability over 2 years

    80% confidence
  • The long sought killer use case for quantum is quantum optimization, and evidence shows only annealing quantum systems will deliver speed-up on quantum optimization

    80% confidence
  • Go-to-market hiring expected to complete by mid-Q1 2025

    80% confidence
  • D-Wave's intellectual property covers both annealing AND gate model technologies, with majority of 240+ US granted patents covering both

    80% confidence
  • D-Wave aims to achieve profitability with substantially less funding than competitors

    80% confidence
  • D-Wave goal is to be the first independent public quantum company to achieve sustained profitability

    80% confidence
  • Advantage 2 will be added to Leap cloud service sooner rather than later

    80% confidence
  • Q4 bookings expected to improve over Q3

    80% confidence
  • D-Wave does not sell to China or Chinese companies due to US and Canada government restrictions

    80% confidence
  • D-Wave is the only quantum company offering formal SLAs

    80% confidence
  • D-Wave shows versatility once thought limited to gate-based systems

    80% confidence
  • Advantage system with 5,000 qubits is the largest and most powerful quantum computer in the world

    80% confidence
  • Work by Chinese researchers shows only quantum system factoring non-trivial numbers is D-Wave annealing

    80% confidence
  • D-Wave's annealing systems are one of few quantum technologies used by organizations to run production use cases to gain business value

    80% confidence
  • D-Wave is the only quantum computing company with commercial production deployments

    80% confidence
  • Production apps generate high $100Ks to $1M+ annual recurring QCaaS revenue

    80% confidence
  • Europe is ahead of US in likely government quantum deployments

    80% confidence
  • FY2024 adjusted EBITDA loss will be less than $54.3M

    80% confidence

Data points we hold from this source

D-Wave Quantum Inc. · gross margin gaap55.8 percent
D-Wave Quantum Inc. · gross margin non gaap67.2 percent
D-Wave Quantum Inc. · lincoln park equity line remaining49.9 million_USD
D-Wave Quantum Inc. · bookings7.4 million_USD
D-Wave Quantum Inc. · adjusted ebitda loss13.8 million_USD
D-Wave Quantum Inc. · atm program remaining79.1 million_USD
D-Wave Quantum Inc. · eps-0.51 USD
D-Wave Quantum Inc. · cash30 million_USD
D-Wave Quantum Inc. · total customers132 customers
D-Wave Quantum Inc. · commercial customers76 customers
D-Wave Quantum Inc. · commercial revenue decrease0.2 million_USD
D-Wave Quantum Inc. · forbes global 2000 customers27 customers
D-Wave Quantum Inc. · research revenue increase0.6 million_USD
D-Wave Quantum Inc. · qcaas revenue5.1 million_USD
D-Wave Quantum Inc. · professional services revenue0.3 million_USD
D-Wave Quantum Inc. · patent count240 patents
D-Wave Quantum Inc. · debt0 million_USD
D-Wave Quantum Inc. · net loss66.7 million_USD
D-Wave Quantum Inc. · government revenue increase0.8 million_USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com